191 related articles for article (PubMed ID: 11268498)
1. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
[TBL] [Abstract][Full Text] [Related]
2. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels.
Mystakidou K; Befon S; Hondros K; Kouskouni E; Vlahos L
J Pain Symptom Manage; 1999 Nov; 18(5):323-30. PubMed ID: 10584455
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
7. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
8. Octreotide in advanced prostatic cancer relapsing under hormonal treatment.
Verhelst J; De Longueville M; Ongena P; Denis L; Mahler C
Acta Urol Belg; 1994 Apr; 62(1):83-8. PubMed ID: 7515212
[TBL] [Abstract][Full Text] [Related]
9. Relationship between pain severity and serum beta-endorphin levels in postoperative patients.
Leonard TM; Klem SA; Asher MA; Rapoff MA; Leff RD
Pharmacotherapy; 1993; 13(4):378-81. PubMed ID: 8361864
[TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
11. Plasma Beta-endorphin levels before and after relief of cancer pain.
El-Sheikh N; Boswell MV
Pain Physician; 2004 Jan; 7(1):67-70. PubMed ID: 16868614
[TBL] [Abstract][Full Text] [Related]
12. Improvement in psychosocial outcomes in chronic pain patients receiving intrathecal morphine infusions.
Duse G; Davià G; White PF
Anesth Analg; 2009 Dec; 109(6):1981-6. PubMed ID: 19923529
[TBL] [Abstract][Full Text] [Related]
13. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
[TBL] [Abstract][Full Text] [Related]
14. The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
Bender T; Donáth J; Barna I; Gergely P; Poór G
Neuro Endocrinol Lett; 2006 Aug; 27(4):513-5. PubMed ID: 16891991
[TBL] [Abstract][Full Text] [Related]
15. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
16. Octreotide inhibits pancreatic exocrine secretion and prevents pancreatoenterostomy leakage.
Nakatsuka A; Yamaguchi K; Chijiiwa K; Tanaka M
Int Surg; 2000; 85(2):124-9. PubMed ID: 11071328
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial.
Abid S; Jafri W; Hamid S; Salih M; Azam Z; Mumtaz K; Shah HA; Abbas Z
Am J Gastroenterol; 2009 Mar; 104(3):617-23. PubMed ID: 19223890
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
20. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
